Return to Chronic Myeloid Leukemia Specialty Channel
Chronic Myeloid Leukemia Newswatch
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
Asciminib is well-tolerated and shows promising clinical activity in patients with Ph+ CML with baseline BCR-ABL1 levels less than 1%.
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings suggest that switching patients with CML-CP from first-line imatinib to dasatinib may at times be beneficial.
Research supports administering nilotinib at a dosage of 300 mg daily for newly diagnosed patients with CML in chronic phase.